Doctors today hailed a breakthrough in the fight against pancreatic cancer after a new drug was shown to give patients precious extra months of life.

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.